Fulgent Genetics (FLGT) Asset Writedowns and Impairment (2015 - 2026)

Fulgent Genetics has disclosed Asset Writedowns and Impairment across 12 years of filings, most recently posting $1.2 million for Q1 2026.

• Asset Writedowns and Impairment for Q1 2026 came in at $1.2 million, down 42.7% year-over-year; the trailing twelve-month figure through Mar 2026 was $13.0 million (down 4.84% YoY), and the FY2025 annual result was $7.6 million, up 542.08% from the prior year.
• Asset Writedowns and Impairment came in at $1.2 million for Q1 2026 at Fulgent Genetics, down from $1.9 million in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $11.6 million in Q1 2022 to a low of -$2.5 million in Q1 2024.
• The 5-year median for Asset Writedowns and Impairment is $2.1 million (2025), against an average of $3.7 million.
• Across the five-year window, Asset Writedowns and Impairment soared 987.78% in 2022 and plunged 2109.73% in 2024, its largest moves.
• Fulgent Genetics' Asset Writedowns and Impairment stood at $7.3 million in 2022, then plunged by 52.7% to $3.5 million in 2023, then tumbled by 57.11% to $1.5 million in 2024, then climbed by 25.27% to $1.9 million in 2025, then plunged by 35.87% to $1.2 million in 2026.
• The last three Asset Writedowns and Impairment figures came in at $1.2 million (Q1 2026), $1.9 million (Q4 2025), and $9.9 million (Q2 2025), per Business Quant data.